AbbVie Hits $266.28 52-Week High on FDA Approval of JUVMO
As seen on the 24/7 Wall St. homepage on September 28, 2026.
AbbVie cleared its August record with a fresh 52-week high at $266.28, 0.12% above the prior peak, on the same day it announced FDA approval of JUVMO. A $470.9 billion pharma making new highs is a momentum signal income investors rarely get.
Continue ReadingShow less
AbbVie set a fresh 52-week high at $266.28 on the same day the FDA approved JUVMO, giving the rally a concrete catalyst.
For a company carrying a $470.9 billion market cap, breaking to new highs is harder than it sounds. Large-cap pharma at that scale tends to move in slow arcs, so a clean breakout above a recent record carries more weight than the fractional percentage gap alone suggests.
The FDA approval of JUVMO adds a new commercial asset to AbbVie's portfolio at a moment when the stock is already in price-discovery territory above its prior ceiling. Investors who track momentum signals alongside product-cycle catalysts are looking at both boxes checked simultaneously.
The prior 52-week high was set on August 19, 2026, after which the stock consolidated before pushing through. Income-oriented investors, drawn to AbbVie partly for its dividend history, rarely see this kind of momentum alignment with a pipeline event.
Sources
Mentioned: ABBV